Live from Leesburg: AMT-260, Neurona, and Why Context Matters

Epilepsy Foundation Pipeline Conference, June 19, 2026

This will be a “best ideas only” bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.

I am writing this from Leesburg, Virginia, where I spent Friday at the Epilepsy Foundation Pipeline Conference — the same room where uniQure presented preliminary data from the first cohort of its GenTLE Phase 1/2a trial of AMT-260 in refractory mesial temporal lobe epilepsy, and where Neurona Therapeutics presented updated data on rezanecel in the same indication. A significant amount of commentary has already gone out framing today’s AMT-260 readout as mixed or disappointing, and I want to offer some nuance, because being in the room produces a materially different picture than reading a press release from the outside.